• Je něco špatně v tomto záznamu ?

Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors

M. Kolcheva, S. Kortus, BH. Krausova, P. Barackova, A. Misiachna, S. Danacikova, M. Kaniakova, K. Hemelikova, M. Hotovec, K. Rehakova, M. Horak

. 2021 ; 189 (-) : 108528. [pub] 20210325

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004344

N-methyl-d-aspartate receptors (NMDARs) play an essential role in regulating glutamatergic neurotransmission. Recently, pathogenic missense mutations were identified in genes encoding NMDAR subunits; however, their effect on NMDAR activity is often poorly understood. Here, we examined whether three previously identified pathogenic mutations (M641I, A645S, and Y647S) in the M3 domain of the GluN1 subunit affect the receptor's surface delivery, agonist sensitivity, Mg2+ block, and/or inhibition by the FDA-approved NMDAR blocker memantine. When expressed in HEK293 cells, we found reduced surface expression of GluN1-M641I/GluN2A, GluN1-Y647S/GluN2A, and GluN1-Y647S/GluN2B receptors; other mutation-bearing NMDAR combinations, including GluN1/GluN3A receptors, were expressed at normal surface levels. When expressed in rat hippocampal neurons, we consistently found reduced surface expression of the GluN1-M641I and GluN1-Y647S subunits when compared with wild-type GluN1 subunit. At the functional level, we found that GluN1-M641I/GluN2 and GluN1-A645S/GluN2 receptors expressed in HEK293 cells have wild-type EC50 values for both glutamate and glycine; in contrast, GluN1-Y647S/GluN2 receptors do not produce glutamate-induced currents. In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Finally, we found that memantine was the most neuroprotective in hippocampal neurons expressing GluN1-M641I subunits, followed by neurons expressing wild-type GluN1 and then GluN1-A645S subunits in an NMDA-induced excitotoxicity assay. These results indicate that specific pathogenic mutations in the M3 domain of the GluN1 subunit differentially affect the trafficking and functional properties of NMDARs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004344
003      
CZ-PrNML
005      
20220127145327.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neuropharm.2021.108528 $2 doi
035    __
$a (PubMed)33773999
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kolcheva, Marharyta $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic; Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, 12843, Prague 2, Czech Republic; Laboratory of Cellular Neurophysiology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
245    10
$a Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors / $c M. Kolcheva, S. Kortus, BH. Krausova, P. Barackova, A. Misiachna, S. Danacikova, M. Kaniakova, K. Hemelikova, M. Hotovec, K. Rehakova, M. Horak
520    9_
$a N-methyl-d-aspartate receptors (NMDARs) play an essential role in regulating glutamatergic neurotransmission. Recently, pathogenic missense mutations were identified in genes encoding NMDAR subunits; however, their effect on NMDAR activity is often poorly understood. Here, we examined whether three previously identified pathogenic mutations (M641I, A645S, and Y647S) in the M3 domain of the GluN1 subunit affect the receptor's surface delivery, agonist sensitivity, Mg2+ block, and/or inhibition by the FDA-approved NMDAR blocker memantine. When expressed in HEK293 cells, we found reduced surface expression of GluN1-M641I/GluN2A, GluN1-Y647S/GluN2A, and GluN1-Y647S/GluN2B receptors; other mutation-bearing NMDAR combinations, including GluN1/GluN3A receptors, were expressed at normal surface levels. When expressed in rat hippocampal neurons, we consistently found reduced surface expression of the GluN1-M641I and GluN1-Y647S subunits when compared with wild-type GluN1 subunit. At the functional level, we found that GluN1-M641I/GluN2 and GluN1-A645S/GluN2 receptors expressed in HEK293 cells have wild-type EC50 values for both glutamate and glycine; in contrast, GluN1-Y647S/GluN2 receptors do not produce glutamate-induced currents. In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Finally, we found that memantine was the most neuroprotective in hippocampal neurons expressing GluN1-M641I subunits, followed by neurons expressing wild-type GluN1 and then GluN1-A645S subunits in an NMDA-induced excitotoxicity assay. These results indicate that specific pathogenic mutations in the M3 domain of the GluN1 subunit differentially affect the trafficking and functional properties of NMDARs.
650    _2
$a zvířata $7 D000818
650    _2
$a kultivované buňky $7 D002478
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a agonisté excitačních aminokyselin $x aplikace a dávkování $7 D018690
650    _2
$a antagonisté excitačních aminokyselin $x aplikace a dávkování $7 D018691
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a hipokampus $x účinky léků $x fyziologie $7 D006624
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $x účinky léků $x genetika $7 D009154
650    _2
$a proteiny nervové tkáně $x agonisté $x antagonisté a inhibitory $x genetika $7 D009419
650    _2
$a podjednotky proteinů $x agonisté $x antagonisté a inhibitory $x genetika $7 D021122
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory N-methyl-D-aspartátu $x agonisté $x antagonisté a inhibitory $x genetika $7 D016194
650    _2
$a povrchové vlastnosti $x účinky léků $7 D013499
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kortus, Stepan $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Krausova, Barbora Hrcka $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Barackova, Petra $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Misiachna, Anna $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Danacikova, Sarka $u Laboratory of Cellular Neurophysiology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Kaniakova, Martina $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Hemelikova, Katarina $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Hotovec, Matej $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Rehakova, Kristyna $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
700    1_
$a Horak, Martin $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic. Electronic address: martin.horak@iem.cas.cz
773    0_
$w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 189, č. - (2021), s. 108528
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33773999 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145324 $b ABA008
999    __
$a ok $b bmc $g 1751719 $s 1155493
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 189 $c - $d 108528 $e 20210325 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace